Marinus Pharmaceuticals Inc

Marinus Pharmaceuticals — Investor Presentation (March 2024)

51 slides from Marinus Pharmaceuticals's investor presentation, Mar 5, 2024

  1. Slide 1: Corporate Presentation March 2024

    Nasdaq: MRNS @MarinusPharma Photo Credit: Kelly Crews Photography Ryan (center) Living with CDKL5 deficiency disorder Corporate Presentation March 2024

  2. Slide 2: Forward-looking statements

    ©2024 Marinus Pharmaceuticals. All Rights Reserved I To the extent that statements contained in this presentation are not descriptions of historical facts regarding Marinus, they are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe ha

  3. Slide 3: Ganaxolone Development Pipeline

    ©2024 Marinus Pharmaceuticals. All Rights Reserved I Ganaxolone Development Pipeline 3 Ganaxolone is a positive allosteric GABAA receptor modulator with a well-defined MOA designed to treat patients suffering from seizure disorders. Ganaxolone is designed to modulate both synaptic and extrasynaptic

  4. Slide 4: Ganaxolone U.S. Market Opportunity

    ©2024 Marinus Pharmaceuticals. All Rights Reserved I 4 ¹Symonds et al. Incidence and phenotypes of childhood-onset genetic epilepsies: a prospective population-based national cohort. Brain. 2019 Aug 1;142(8):2303-2318. ²Curatolo P, Bombardieri R, Jozwiak S. Tuberous sclerosis. Lancet. 2008;372:657–6

  5. Slide 5: Commercial Update

    Commercial Update Not for promotional use

  6. Slide 6: ZTALMY Performance Metrics

    ©2024 Marinus Pharmaceuticals. All Rights Reserved I ZTALMY® Performance Metrics 6 U.S. net product revenue of $6.6M for the fourth quarter of 2023 More than 165 patients active on therapy at the end of 2023 U.S. net product revenue of $32M- $34M expected for the fiscal year 2024 ~225 million covere

  7. Slide 7: A Comprehensive Commercial Strategy to Grow the ZTALMY Brand

    ©2024 Marinus Pharmaceuticals. All Rights Reserved I A Comprehensive Commercial Strategy to Grow the ZTALMY® Brand Patient identification Activate the caregiver community Focused education to HCPs to establish ZTALMY as the standard of care for CDD seizure management Continuously enhance the patient

  8. Slide 8: Tuberous Sclerosis Complex

    Tuberous Sclerosis Complex “Many individuals with TSC continue to experience uncontrolled seizures despite a cocktail of multiple antiepileptic drugs. Because new options are always needed, the TSC community welcomes clinical evaluation of new epilepsy treatments” - Kari Luther Rosbeck, President &

  9. Slide 9: Tuberous Sclerosis Complex (TSC)

    ©2024 Marinus Pharmaceuticals. All Rights Reserved I 9 Tuberous Sclerosis Complex (TSC) CAUSE • Defect or mutation of TSC1 and/or TSC2 genes INCIDENCE • ~1 in 6,000 live births1 COMMON SYMPTOMS • Seizures, cognitive impairment, behavioral difficulties, skin/kidney/lung abnormalities, etc EPILEPSY IN

  10. Slide 10: TSC Phase 2 Trial Results

    ©2024 Marinus Pharmaceuticals. All Rights Reserved I TSC Phase 2 Trial Results 10 * -200 -100 -80 -60 -40 -20 0 20 40 60 80 100 Percent reduction in TSC-associated seizure frequency =median 16.6% Secondary and Exploratory Analyses Primary Endpoint Results: 16.6% median reduction in TSC-associated se

  11. Slide 11: Phase 3 Protocol Refinements Informed by Phase 2

    ©2024 Marinus Pharmaceuticals. All Rights Reserved I Phase 3 Protocol Refinements Informed by Phase 2 11 Phase 3 Slower titration initially, designed to optimize tolerability and improve efficacy No (n=6) Yes (n=17) 0 5 10 15 20 25 30 Somnolence-related AE Percentreduction in TSC-associated seizure

  12. Slide 12: Phase 3 Trial Overview

    ©2024 Marinus Pharmaceuticals. All Rights Reserved I Phase 3 Trial Overview 12 ► Enrollment: ~128 patients, targeting sites in the U.S., Western Europe, Canada, Israel, Australia and China • 90% powered to detect a 25% treatment difference • Statistical significance could be achieved with a treatmen

  13. Slide 13: TrustTSC Baseline Demographics

    ©2024 Marinus Pharmaceuticals. All Rights Reserved I TrustTSC Baseline Demographics 13 Age (mean [min-max]) 15 [1-50] Gender 52% male 48% female Failed ASMs* (mean) 4.3 Baseline Seizure Rate (median, per 28 days) 42 DB Discontinuation Rate** <7% only 2 discontinuations due to somnolence-related adve

  14. Slide 14: Addressable Patient Population

    ©2024 Marinus Pharmaceuticals. All Rights Reserved I Addressable Patient Population ~2,000 9.6-11k 40% Highly Refractory4 CDD Patients5 TSC Highly Refractory CDD Patients TSC Epileptic TSC Prevalence TSC Refractory TSC CDD 24-28k 60-65% Refractory3 40-43k 80-85% Epileptic2,3 50,000 1/6000 incidence1

  15. Slide 15: Leverage of Existing ZTALMY Infrastructure to TSC

    ©2024 Marinus Pharmaceuticals. All Rights Reserved I Leverage of Existing ZTALMY® Infrastructure to TSC Expected to Yield Significant Return with Modest Expansion 15 15 TSC COMMERCIAL INFRASTRUCTURE Modest increase in field force MARKETING STRATEGY Distinct TSC positioning EXPANDED TARGETS Significa

  16. Slide 16: Status Epilepticus

    Status Epilepticus

  17. Slide 17: Status Epilepticus Overview

    ©2024 Marinus Pharmaceuticals. All Rights Reserved I Status Epilepticus Overview 17 Status Epilepticus = Condition resulting from either the failure of the mechanisms responsible for seizure termination or from the initiation of mechanisms which lead to: • abnormally prolonged seizures (after time p

  18. Slide 18: Pharmacokinetics/Pharmacodynamics Well Suited for Acute SE Treatment

    ©2024 Marinus Pharmaceuticals. All Rights Reserved I 18 Pharmacokinetics/Pharmacodynamics Well Suited for Acute SE Treatment Experimental PK – plasma and brain1 Brain and plasma concentration after ganaxolone 3 mg/kg IM in mice Human PD – EEG changes2 EEG bispectral index in healthy volunteers follo

  19. Slide 19: Strategic Approach to SE Clinical Development

    ©2024 Marinus Pharmaceuticals. All Rights Reserved I Strategic Approach to SE Clinical Development 19 1. DeLorenzo RJ Pellock JM Towne AR Boggs JG. Epidemiology of status epilepticus. J Clin Neurophysiol. 1995; 12: 316-325 2. Kapur et al. Randomized Trial of Three Anticonvulsant Medications for Stat

  20. Slide 20: Refractory Status Epilepticus Trial (RSE) Design

    ©2024 Marinus Pharmaceuticals. All Rights Reserved I Treatment Period Loading Dose Maintenance Taper 20 Phase 2 Refractory Status Epilepticus Trial (RSE) Design • Diagnosis of convulsive or non-convulsive SE • Failed at least one 2nd line IV AED but had not progressed to 3rd line IV anesthetics Bolu

  21. Slide 21: Phase 2 Trial Results Demonstrated Rapid Onset And Durability of Effect

    ©2024 Marinus Pharmaceuticals. All Rights Reserved I 21 Phase 2 Trial Results Demonstrated Rapid Onset And Durability of Effect Data presented at AES 2019 AEDs – antiepileptic drugs Cohort No escalation to IV anesthetics within 24 hours from infusion initiation (Primary Endpoint) Status-free through

  22. Slide 22: PK/PD Relationship and Rationale for Target Dose

    ©2024 Marinus Pharmaceuticals. All Rights Reserved I PK/PD Relationship and Rationale for Target Dose 22 22 PK model estimations Vaitkevicius H et al. Intravenous ganaxolone for the treatment of refractory status epilepticus: Results from an open-label, dose-finding, phase 2 trial. Epilepsia. 2022 S

  23. Slide 23: RAISE: Phase 3 Trial in Refractory Status Epilepticus

    ©2024 Marinus Pharmaceuticals. All Rights Reserved I Patient Population Study Treatment RAISE: Phase 3 Trial in Refractory Status Epilepticus 23 *SE, status epilepticus; SRSE, super refractory status epilepticus; IV, intravenous; ASM, antiseizure medication; IV ASMs: fosphenytoin/phenytoin, levetira

  24. Slide 24: RAISE Trial: Baseline Patient Characteristics

    ©2024 Marinus Pharmaceuticals. All Rights Reserved I RAISE Trial: Baseline Patient Characteristics* 24 Phase 2 RSE Study (17 patients)1 Phase 3 RAISE Study *This is preliminary RAISE data for the interim analysis STESS: mean (range) Severity of the RAISE population ASM utilization in RAISE # IV ASMs

  25. Slide 25: RAISE Endpoints and Interim Analysis

    ©2024 Marinus Pharmaceuticals. All Rights Reserved I RAISE Endpoints and Interim Analysis 25 OTHER SECONDARY ENDPOINTS §Medications for the acute treatment of SE are defined as ASMs administered to abort ongoing SE or prevent imminent recurrence of SE based on clinical or EEG evidence. This definiti

  26. Slide 26: RAISE II: Phase 3 Trial in Refractory Status Epilepticus

    ©2024 Marinus Pharmaceuticals. All Rights Reserved I RAISE II: Phase 3 Trial in Refractory Status Epilepticus 26 1 Kapur et al. Randomized Trial of Three Anticonvulsant Medications for Status Epilepticus N Engl J Med 2019;381:2103-13. Benzodiazepine Administered IV AEDs (antiepileptic drugs) IV Anes

  27. Slide 27: Published Research Suggests Early Treatment Intervention May Improve Outcomes

    ©2024 Marinus Pharmaceuticals. All Rights Reserved I Published Research Suggests Early Treatment Intervention May Improve Clinical Outcomes 27 Status epilepticus (SE) duration ≥12 hours was an independent predictor of an unfavorable outcome at discharge in patients with post-stroke SE (OR 9.58 (1.97

  28. Slide 28: Approach to SRSE

    ©2024 Marinus Pharmaceuticals. All Rights Reserved I ► Novel dosing approach and current EINDs • ↓Cmax but ↑ AUC + 3 month oral wean • Ganaxolone 833mg/day x 48h➛1,050mg/day x 168h • Captisol® 50gm/day ➛63gm/day Approach to SRSE 28 26 patients with SRSE treated to date with IV ganaxolone 14 with sim

  29. Slide 29: Super Refractory Status Epilepticus: Ganaxolone Experience to Date

    ©2024 Marinus Pharmaceuticals. All Rights Reserved I Super Refractory Status Epilepticus: Ganaxolone Experience to Date 29 New onset refractory status epilepticus (NORSE) Febrile illness-related epilepsy syndrome (FIRES) Lennox-Gastaut syndrome PCDH-19 related epilepsy Autoimmune encephalitis Herpes

  30. Slide 30: Building Commercial Infrastructure for Future IV Launches

    Building Commercial Infrastructure for Future IV Launches

  31. Slide 31: Roadmap to Success in the Hospital Market

    ©2024 Marinus Pharmaceuticals. All Rights Reserved I Roadmap to Success in the Hospital Market 31 31 Charting our own path to deliver a groundbreaking treatment for patients with refractory status epilepticus Market Segmentation & Targeting Robust Total Value Proposition Advanced analytics as a GPS

  32. Slide 32: RSE Commercial Launch Preparedness

    ©2024 Marinus Pharmaceuticals. All Rights Reserved I RSE Commercial Launch Preparedness 32 T O P - L I N E D A T A N D A F I L I N G P D U F A L A U N C H Commercial Infrastructure Clinical Stakeholders Payors Hospital Formulary Financial Decision-Makers NTAP/Reimbursement Driving awareness through

  33. Slide 33: Outcomes Deteriorate as RSE Progresses Despite Intensive Levels of Care

    ©2024 Marinus Pharmaceuticals. All Rights Reserved I Outcomes Deteriorate as RSE Progresses Despite Intensive Levels of Care As SE progresses, healthcare resource utilization increases, but patient outcomes worsen IV anti-seizure meds Medically-induced coma with IV anesthetics Progression to ≥ 3 ASM

  34. Slide 34: Clinical and Healthcare Costs Associated with RSE

    ©2024 Marinus Pharmaceuticals. All Rights Reserved I Clinical and Healthcare Costs Associated with RSE 34 Utilization and Cost Outcomes Metric Cohort 1 (≤ 1 IV AED) Cohort 2 (> 1 IV AED) Cohort 3 (≥ 1 IV anesthetic) All Unique RSE patient encounter, N (%) 14,694 (33.4) 10,140 (23.1) 19,154 (43.5) 43

  35. Slide 35: Second Generation Product Development

    Second Generation Product Development

  36. Slide 36: Second Generation Ganaxolone Goals

    ©2024 Marinus Pharmaceuticals. All Rights Reserved I Second Generation Ganaxolone 36 Goals Target Oral Pharmacokinetic Profile Increase efficacy Consistent delivery to achieve target plasma concentration Improve tolerability Optimize PK profile to reduce Cmax-related adverse effects Reduce dosing fr

  37. Slide 37: Next Steps: Prodrug and Ganaxolone Reformulation

    ©2024 Marinus Pharmaceuticals. All Rights Reserved I Next Steps: Prodrug and Ganaxolone Reformulation 37 Ganaxolone Prodrug Oral prodrug candidate selected Goals: • Optimize PK parameters for efficacy, tolerability and dosing frequency • Increase absorption (oral), solubility (IV) Preclinical IND-en

  38. Slide 38: Financial Update

    Financial Update

  39. Slide 39: Financial Overview

    ©2024 Marinus Pharmaceuticals. All Rights Reserved I Financial Overview 39 Analyst Coverage*: Cantor Fitzgerald: Charles C. Duncan, Ph.D. Cowen: Joseph Thome, Ph.D. H.C. Wainwright & Co: Douglas Tsao Jefferies: Andrew Tsai JMP Securities: Jason N. Butler, Ph.D. Ladenburg Thalmann: Michael Higgins Op

  40. Slide 40: Driving Global Access of ZTALMY (ganaxolone)

    ©2024 Marinus Pharmaceuticals. All Rights Reserved I Driving Global Access of ZTALMY® (ganaxolone) 40 Europe: Collaboration agreement with Orion Corporation for ganaxolone in CDD, TSC, RSE • Up to €90 million of development, commercial, and sales milestones1 ; tiered royalties in the low double-digi

  41. Slide 41: Intellectual Property

    Intellectual Property

  42. Slide 42: Multiple Layers Of Potential Protection

    ©2024 Marinus Pharmaceuticals. All Rights Reserved I Multiple Layers Of Potential Protection 42 Orphan drug designations for CDD and PCDH19 provide 7 and 10 years regulatory exclusivity in U.S. and EU, respectively. Orphan drug designation for SE provides 7 years regulatory exclusivity in U.S. U.S.

  43. Slide 43: Appendix

    Appendix (® MARINUS

  44. Slide 44: Phase 3 CDD Marigold Trial Data and Safety Summary

    ©2024 Marinus Pharmaceuticals. All Rights Reserved I 44 Ganaxolone Placebo 0 10 20 30 40 Median Percent Reduction 28-day Frequency of Major Motor Seizures 30.7% 6.9% *Wilcoxon Rank-Sum Test **Hodges-Lehman Estimate of Median Dif erence Patients taking ganaxolone experienced a significant reduction i

  45. Slide 45: Average Ganaxolone Levels Correlate with Seizure Reduction

    ©2024 Marinus Pharmaceuticals. All Rights Reserved I Average Ganaxolone Levels Correlate with Seizure Reduction 45 • Logarithms of plasma ganaxolone level and percentage change in major motor seizure frequency were negatively correlated • Patients in the Medium and High ganaxolone level groups had a

  46. Slide 46: Phase 3 Open Label Extension Data in CDD

    ©2024 Marinus Pharmaceuticals. All Rights Reserved I 46 Reduction in monthly major motor seizure frequency through 2 years of the OLE* Patients who remained in the clinical trial at 2 years experienced sustained reduction in MMSF1 ► Following the pivotal trial, 88 out of 101 patients entered an open

  47. Slide 47: Details on Baseline Patient Characteristics for Phase 2 RSE Trial

    ©2024 Marinus Pharmaceuticals. All Rights Reserved I 47 Details on Baseline Patient Characteristics for Phase 2 RSE Trial NCSE: Non-convulsive status epilepticus CSE: Convulsive status epilepticus LAC: Lacosamide LEV: Levetiracetam LOR: Lorazepam PHT: Phenytoin fPHT: Fosphenytoin VPA: Valproic Acid

  48. Slide 48: PK/PD Relationship and Rationale for Target Dose

    ©2024 Marinus Pharmaceuticals. All Rights Reserved I 48 PK/PD Relationship and Rationale for Target Dose Modeled PK Curves for All Dose Groups High Dose Achieved Target Range ≥ 500 ng/mL for ~8 hours Only High Dose Provided Sustained Reduction (>80%) Throughout Entire Analysis Window Data presented

  49. Slide 49: RAISE Trial Sites Standard of Care Progression to IV Anesthesia

    ©2024 Marinus Pharmaceuticals. All Rights Reserved I 49 RAISE Trial Sites Standard of Care Progression to IV Anesthesia ► Surveyed PI’s at selected RAISE Trial sites to learn more about their standard of care natural history progression to IV anesthesia following the failure of one versus more than

  50. Slide 50: RAISE Protocol Amended to Accelerate Enrollment

    ©2024 Marinus Pharmaceuticals. All Rights Reserved I RAISE Protocol Amended to Accelerate Enrollment 50 Original Protocol Amended Protocol Patients excluded IF SE would NOT warrant anesthesia for the next 24 hours IV anesthesia would likely be next treatment if study drug (ganaxolone or placebo) doe

  51. Slide 51: Phase 1 Single Ascending Dose (SAD) Study

    ©2024 Marinus Pharmaceuticals. All Rights Reserved I Phase 1 Single Ascending Dose (SAD) Study 51 51 Mean Cmax (ng/mL) Mean AUC0-t (h*ng/mL) 41% 31% 38% 18% 18% 14% Study design Ganaxolone reformulation demonstrated linear kinetics at single doses from 100-1200 mg • Single dose PK study in healthy a

Marinus Pharmaceuticals — Investor Presentation (March 2024) on 6ix